Biobanking | Genomic Research | Diversity

Why Hematologic Cancers?

Leukemias, lymphomas, and myelomas represent a disproportionate share of cancer burden in Africa, yet remain severely underrepresented in global genomic datasets. Differences in disease biology, age of onset, presentation, and outcomes compared to high-income countries remain poorly characterized.

This gap limits:

• Accurate risk stratification

• Biomarker discovery

• Therapy optimization

• Clinical trial relevance

CAICG was founded to address this unmet need—by focusing deliberately and rigorously on blood cancers as a first and foundational priority.

Precision Oncology Enablement

We collaborate with clinicians, hospitals, and research partners to translate genomic findings into:

• Improved diagnostic classification

• Biomarker-guided therapy selection

• Eligibility for clinical trials

Biobanking & Data Infrastructure

CAICG is developing a secure, ethically governed biobank and data ecosystem for:

• Tumor tissue

• Blood and germline samples

• Matched clinical and outcomes data

All samples are collected and managed in alignment with international best practices for consent, privacy, and data stewardship.

Our Mission

To ethically collect, curate, and translate high-quality biospecimens, genomic data, and longitudinal clinical information from African patients with hematologic malignancies—enabling precision oncology research, clinical innovation, and sustainable scientific collaboration.

“There is no such thing as incurable. There are only things for which man has not found a cure”

Bernard Mannes Baruch.